MX2020007771A - Metodos para la supervision de la deteccion y el tratamiento de cancer de colon. - Google Patents
Metodos para la supervision de la deteccion y el tratamiento de cancer de colon.Info
- Publication number
- MX2020007771A MX2020007771A MX2020007771A MX2020007771A MX2020007771A MX 2020007771 A MX2020007771 A MX 2020007771A MX 2020007771 A MX2020007771 A MX 2020007771A MX 2020007771 A MX2020007771 A MX 2020007771A MX 2020007771 A MX2020007771 A MX 2020007771A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- colon cancer
- cancer detection
- treatment monitoring
- determining
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioethics (AREA)
- Databases & Information Systems (AREA)
- Evolutionary Computation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862620015P | 2018-01-22 | 2018-01-22 | |
| PCT/US2019/014490 WO2019144099A1 (en) | 2018-01-22 | 2019-01-22 | Methods for colon cancer detection and treatment monitoring |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020007771A true MX2020007771A (es) | 2020-09-03 |
Family
ID=65279827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020007771A MX2020007771A (es) | 2018-01-22 | 2019-01-22 | Metodos para la supervision de la deteccion y el tratamiento de cancer de colon. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11414707B2 (https=) |
| EP (1) | EP3743534B1 (https=) |
| JP (1) | JP7297770B2 (https=) |
| KR (1) | KR20200113237A (https=) |
| CN (1) | CN112004945B (https=) |
| AU (1) | AU2019209436B2 (https=) |
| BR (1) | BR112020014737A2 (https=) |
| CA (1) | CA3088754A1 (https=) |
| DK (1) | DK3743534T3 (https=) |
| ES (1) | ES2917629T3 (https=) |
| IL (1) | IL276089B2 (https=) |
| MX (1) | MX2020007771A (https=) |
| PL (1) | PL3743534T3 (https=) |
| SG (1) | SG11202006974WA (https=) |
| WO (1) | WO2019144099A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3743534T3 (pl) | 2018-01-22 | 2022-09-05 | Liquid Biopsy Research LLC | Sposoby wykrywania nowotworu okrężnicy i monitorowania leczenia |
| MX2022004372A (es) | 2019-10-10 | 2022-07-27 | Liquid Biopsy Res Llc | Composiciones, métodos y kits para la estabilización de muestras biológicas y de arn. |
| US11809379B2 (en) * | 2019-11-19 | 2023-11-07 | International Business Machines Corporation | Storage tiering for deduplicated storage environments |
| CN111157745A (zh) * | 2020-01-17 | 2020-05-15 | 上海交通大学 | 人snrpa蛋白在肺癌复发或转移监测中的用途 |
| CN115475247B (zh) * | 2021-06-16 | 2024-02-20 | 厦门大学 | β2-微球蛋白或其抑制剂的制药用途 |
| KR102823777B1 (ko) * | 2021-10-15 | 2025-06-23 | 한국과학기술원 | 인공지능을 이용하여 유전체 염기서열로 질환 진단 및 예측 방법, 그 시스템 |
| CN113921079B (zh) * | 2021-12-06 | 2022-03-18 | 四川省肿瘤医院 | 基于免疫相关基因的msi预测模型构建方法 |
| CN121137146B (zh) * | 2025-07-28 | 2026-04-07 | 首钢医院有限公司 | 检测基因组合物的试剂在制备预测结直肠癌患者远端切缘长度的产品中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2169077A1 (en) * | 2008-09-19 | 2010-03-31 | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg | Methods and compositions for diagnosing an adenocarcinoma |
| EP2169078A1 (en) | 2008-09-26 | 2010-03-31 | Fundacion Gaiker | Methods and kits for the diagnosis and the staging of colorectal cancer |
| KR101051435B1 (ko) * | 2008-10-22 | 2011-07-22 | 한국생명공학연구원 | 대장암 관련 마커를 이용한 대장암 진단 키트 및 이를 이용한 대장암 진단 방법 |
| KR101073875B1 (ko) | 2008-11-28 | 2011-10-14 | 한국생명공학연구원 | 대장암 진단 마커 및 이를 이용한 대장암 진단방법 |
| SG10201401722XA (en) | 2009-05-01 | 2014-08-28 | Genomic Health Inc | Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer andresponse to chemotherapy |
| EP2309002A1 (en) * | 2009-09-29 | 2011-04-13 | Centre National de la Recherche Scientifique (CNRS) | Signature for the diagnosis of colorectal cancer aggressiveness |
| ES2525382T3 (es) * | 2010-03-31 | 2014-12-23 | Sividon Diagnostics Gmbh | Método para la predicción de recurrencia del cáncer de mama bajo tratamiento endocrino |
| EP2426216A1 (en) * | 2010-09-01 | 2012-03-07 | Institut Gustave Roussy (IGR) | Prognostic and/or predictive biomarkers and biological applications thereof |
| CN103403187A (zh) | 2011-01-18 | 2013-11-20 | 艾沃锐斯特基因有限公司 | 结肠直肠癌复发的预后特征 |
| JP2014509189A (ja) | 2011-01-25 | 2014-04-17 | アルマック ダイアグノスティックス リミテッド | 結腸ガン遺伝子発現シグネチャーおよび使用方法 |
| US20150226744A1 (en) * | 2012-09-17 | 2015-08-13 | Ait Austrian Institute Of Technology Gmbh | Colon Cancer Diagnostic Method and Means |
| WO2014085826A2 (en) * | 2012-11-30 | 2014-06-05 | Applied Proteomics, Inc. | Method for evaluation of presence of or risk of colon tumors |
| EP2985296A1 (en) * | 2014-08-13 | 2016-02-17 | Calypso Biotech SA | Antibodies specific for MMP9 |
| PL3743534T3 (pl) | 2018-01-22 | 2022-09-05 | Liquid Biopsy Research LLC | Sposoby wykrywania nowotworu okrężnicy i monitorowania leczenia |
-
2019
- 2019-01-22 PL PL19703616.3T patent/PL3743534T3/pl unknown
- 2019-01-22 AU AU2019209436A patent/AU2019209436B2/en active Active
- 2019-01-22 US US16/253,697 patent/US11414707B2/en active Active
- 2019-01-22 IL IL276089A patent/IL276089B2/en unknown
- 2019-01-22 WO PCT/US2019/014490 patent/WO2019144099A1/en not_active Ceased
- 2019-01-22 EP EP19703616.3A patent/EP3743534B1/en active Active
- 2019-01-22 CN CN201980020784.5A patent/CN112004945B/zh active Active
- 2019-01-22 SG SG11202006974WA patent/SG11202006974WA/en unknown
- 2019-01-22 ES ES19703616T patent/ES2917629T3/es active Active
- 2019-01-22 JP JP2020540396A patent/JP7297770B2/ja active Active
- 2019-01-22 BR BR112020014737-0A patent/BR112020014737A2/pt unknown
- 2019-01-22 KR KR1020207024237A patent/KR20200113237A/ko not_active Ceased
- 2019-01-22 MX MX2020007771A patent/MX2020007771A/es unknown
- 2019-01-22 DK DK19703616.3T patent/DK3743534T3/da active
- 2019-01-22 CA CA3088754A patent/CA3088754A1/en active Pending
-
2022
- 2022-07-26 US US17/815,008 patent/US12305240B2/en active Active
-
2025
- 2025-04-18 US US19/182,871 patent/US20250243553A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3088754A1 (en) | 2019-07-25 |
| JP2021511057A (ja) | 2021-05-06 |
| EP3743534A1 (en) | 2020-12-02 |
| SG11202006974WA (en) | 2020-08-28 |
| IL276089A (en) | 2020-08-31 |
| IL276089B2 (en) | 2024-07-01 |
| AU2019209436B2 (en) | 2025-06-05 |
| AU2019209436A1 (en) | 2020-08-06 |
| DK3743534T3 (da) | 2022-06-20 |
| CN112004945A (zh) | 2020-11-27 |
| EP3743534B1 (en) | 2022-03-23 |
| KR20200113237A (ko) | 2020-10-06 |
| US20230220482A1 (en) | 2023-07-13 |
| PL3743534T3 (pl) | 2022-09-05 |
| WO2019144099A1 (en) | 2019-07-25 |
| IL276089B1 (en) | 2024-03-01 |
| US20250243553A1 (en) | 2025-07-31 |
| BR112020014737A2 (pt) | 2020-12-08 |
| JP7297770B2 (ja) | 2023-06-26 |
| US20190226030A1 (en) | 2019-07-25 |
| US11414707B2 (en) | 2022-08-16 |
| ES2917629T3 (es) | 2022-07-11 |
| CN112004945B (zh) | 2025-02-14 |
| US12305240B2 (en) | 2025-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020007771A (es) | Metodos para la supervision de la deteccion y el tratamiento de cancer de colon. | |
| EA201790211A1 (ru) | Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака | |
| CY1125020T1 (el) | Mrna δεικτες βασιζομενοι σε ολικο αιμα για την προβλεψη του καρκινου προστατη και μεθοδοι ανιχνευσης αυτων | |
| EA201792642A1 (ru) | Способы диагностики для т-клеточной терапии | |
| WO2015109263A3 (en) | Biomarkers for detecting and monitoring colon cancer | |
| EA201791578A1 (ru) | Панель биомаркеров для обнаружения рака | |
| MA39776A (fr) | Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf | |
| EA201500835A1 (ru) | Терапевтическая и диагностическая мишень для рака, включающая dll3-связывающие реагенты | |
| MX2020010947A (es) | Metodos de tratamiento de enfermedad de alzheimer. | |
| EP4513187A3 (en) | Methods of detecting prostate cancer | |
| WO2018136919A3 (en) | Methods relating to lung cancer | |
| MX2016007066A (es) | Identificacion de marcadores biologicos predictivos asociados con inhibidores de la via de wnt. | |
| MX2016004283A (es) | Biomarcadores para la actividad, e intesidad y arrebato de la enfermedad lupus eritematoso sistemico. | |
| EA201691314A1 (ru) | Терапевтические способы и композиции | |
| WO2014042828A3 (en) | Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia | |
| WO2017057778A3 (en) | Use of laminin 2 for diagnosing hepatocellular carcinoma and pancreatic cancer | |
| WO2012019132A3 (en) | Anaplastic lymphoma kinase in kidney cancer | |
| HK1232290A1 (zh) | 检测人类骨膜蛋白的新型测定 | |
| EP3693742A3 (en) | Methods of detecting prostate cancer | |
| WO2015077342A3 (en) | Detection of arginine methylation of egfr for prediction of resistance to therapy | |
| MX2020000785A (es) | Metodos para la deteccion de discrasia de celulas plasmaticas. | |
| EP3640643A3 (en) | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker | |
| MX369175B (es) | Métodos para detectar mutantes de akt resistentes a fármacos. | |
| GB2510539A (en) | Biomarkers of cancer | |
| MX2020006388A (es) | Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea. |